A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids
This study was designed to determine the safety and effectiveness of 3 asoprisnil doses compared to placebo, taken for 12 weeks by women with uterine fibroids.
Leiomyoma
DRUG: Asoprisnil|DRUG: Asoprisnil|DRUG: Asoprisnil|DRUG: Placebo
Percent change from baseline in uterine volume and volume of the largest fibroid., Treatment weeks 4, 8, 12 and Post-treatment months 3 and 6.|Duration of amenorrhea, Day 1 to 1st post treatment menses
Change from baseline in uterine size in gestational weeks., Treatment weeks 4, 8, 12 and Post-treatment months 3 and 6|Number of Subjects in each treatment group achieving> or = to 20% reduction in uterine volume., Week 12 and final visit|Percentage of days with bleeding., Day 1 through end of 1st post-treatment menses|Changes in hematologic and iron parameters., Baseline to each visit|Uterine fibroid symptom improvement., Baseline to each visit|Response to Global Efficacy Question regarding improvement in fibroid symptoms., Week 12 and Final Visit
No medical therapy is currently available for the long-term treatment of uterine fibroids. The objective of this study is to determine the safety and efficacy of asoprisnil 5 mg, 10 mg and 25 mg, compared to placebo, taken daily for 12 weeks by women with one or more uterine fibroids, confirmed by ultrasound. Upon completion, subjects at participating sites will be allowed to enter an open-label extension study